Monofer (Ferric Derisomaltose)

Ferric derisomaltose is a stable iron‑carbohydrate complex that, after intravenous infusion, releases elemental iron. The iron is captured by the reticuloendothelial system, transferred to transferrin, and delivered to the bone marrow, where it supports red blood cell production and restores hemoglobin levels.

The dose of Monofer is individualized by the prescribing clinician based on the patient’s weight, hemoglobin level, iron deficit, and clinical condition. Only a qualified health professional should calculate and prescribe the appropriate amount.

Safety data for ferric derisomaltose in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified health professional.

To order Monofer, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Monofer delivers a large dose of iron in a single infusion, reducing the number of administrations compared with some other IV iron formulations that require multiple sessions. Its carbohydrate‑based complex provides a controlled release of iron, which can result in a lower incidence of acute infusion‑related reactions for many patients.

Monofer must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, allow the product to reach room temperature if required by the administration protocol, and inspect for particulate matter or discoloration.

Monofer is administered as an intravenous infusion by a qualified health professional. The infusion rate and total volume are determined by the prescribed dose and the patient’s clinical status. Monitoring of vital signs is recommended during and after the infusion.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, acute hypotensive shock during infusion, and rare cases of respiratory distress. Prompt recognition and treatment of these events are essential, and patients should be observed closely during administration.

Monofer is contraindicated in patients with known hypersensitivity to ferric derisomaltose or any of its excipients, and in individuals with active iron overload conditions such as hereditary hemochromatosis. Caution is also advised for patients with uncontrolled infections or severe cardiovascular instability.